GRFS

Handel nachbörslich: 9.49 0.06 +0.64%

Grifols Sa Adr (GRFS)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt GRFS? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Grifols Sa Adr Stock (GRFS) Company Profile

Grifols Sa Adr

Healthcare (1136)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

GRFS's Discussions on Twitter

Vergleichen Sie GRFS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GRFS Grifols Sa Adr	9.43	6.38B	7.94B	225.54M	709.16M	0.3299
LLY Lilly Eli Co	896.53	772.28B	59.42B	18.41B	6.44B	20.22
JNJ Johnson Johnson	186.26	455.04B	92.15B	25.12B	20.46B	10.36
ABBV Abbvie Inc	211.96	385.18B	59.64B	2.37B	18.24B	1.331
NVS Novartis Ag Adr	123.86	237.53B	54.45B	14.42B	17.15B	7.333
MRK Merck Co Inc	82.49	214.76B	63.99B	19.05B	14.72B	7.5596

Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-12	Fortgesetzt	Morgan Stanley	Overweight
2024-03-12	Herabstufung	Deutsche Bank	Hold → Sell
2023-04-12	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-03-03	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2023-02-16	Hochstufung	Barclays	Underweight → Equal Weight
2023-01-18	Hochstufung	Jefferies	Hold → Buy
2022-04-08	Eingeleitet	Morgan Stanley	Equal-Weight
2021-11-05	Herabstufung	Deutsche Bank	Buy → Hold
2021-10-19	Herabstufung	Barclays	Overweight → Underweight
2021-10-06	Hochstufung	Citigroup	Neutral → Buy
2021-06-14	Hochstufung	Deutsche Bank	Hold → Buy
2021-04-20	Eingeleitet	Deutsche Bank	Hold
2021-03-23	Hochstufung	Credit Suisse	Neutral → Outperform
2021-03-11	Hochstufung	HSBC Securities	Hold → Buy
2020-10-01	Hochstufung	Citigroup	Sell → Neutral
2020-06-09	Herabstufung	Citigroup	Neutral → Sell
2020-06-09	Hochstufung	HSBC Securities	Reduce → Hold
2020-03-25	Herabstufung	Citigroup	Buy → Neutral
2019-06-27	Hochstufung	JP Morgan	Neutral → Overweight
2019-02-08	Herabstufung	Berenberg	Buy → Hold
2018-10-11	Hochstufung	Berenberg	Hold → Buy
2018-06-01	Eingeleitet	Barclays	Overweight
2017-10-31	Eingeleitet	Citigroup	Buy
2017-06-30	Herabstufung	Goldman	Buy → Neutral
2017-04-06	Eingeleitet	BofA/Merrill	Buy
2017-01-03	Hochstufung	JP Morgan	Neutral → Overweight
2016-02-09	Hochstufung	Berenberg	Hold → Buy
2016-01-04	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2015-12-02	Herabstufung	HSBC Securities	Buy → Hold
2015-11-20	Herabstufung	Berenberg	Buy → Hold
2015-04-28	Herabstufung	Berenberg	Buy → Hold

Alle ansehen

Grifols Sa Adr Aktie (GRFS) Neueste Nachrichten

Finanzdaten der Grifols Sa Adr-Aktie (GRFS)

Grifols Sa Adr (GRFS)

Grifols Sa Adr Stock (GRFS) Company Profile

Vergleichen Sie GRFS mit anderen Aktien

Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades

Grifols Sa Adr Aktie (GRFS) Neueste Nachrichten

Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN

Grifols, S.A.American Depositary Shares (Nasdaq:GRFS) Stock Quote - FinancialContent

Validea Joseph Piotroski Strategy Daily Upgrade Report10/10/2025 - Nasdaq

Arm Holdings PLC ADRhedged (BATS:ARMH) Short Interest Down 33.3% in September - Defense World

Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha

GRDLY Stock Price, Quote and News - Markets.com

Grifols (NASDAQ:GRFS) Share Price Crosses Above 200-Day Moving Average – Should You Sell? - Defense World

Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.

Grifols Announces Interim Dividend for 2025 - The Globe and Mail

CNH Industrial NV (NYSE: CNH) Stock Forecast: Bearish Sentiment Points To -15.21% Downside In 2025 - stocksregister.com

Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - Benzinga

Oppenheimer Asset Management Inc. Acquires 23,980 Shares of Grifols, S.A. (NASDAQ:GRFS) - Defense World

ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com

ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - The Globe and Mail

Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha

Grifols S.A. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

6 undervalued stocks with low beta - Morningstar

Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com

Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha

Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha

Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance

Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance

Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha

Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire

Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire

AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers

The 10 Most-Bought and Most-Sold European Stocks | Morningstar UK - Morningstar Canada

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - PR Newswire

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Grifols, S.A. - GlobeNewswire

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Grifols, - GlobeNewswire

GRFS Stock Quote Price and Forecast - CNN

BreakingviewsShort attack intensifies Grifols’ health problem - Reuters

Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 - PR Newswire

Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - PR Newswire Canada

8 Newly Undervalued 5-Star Stocks - Morningstar

Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 - PR Newswire

Grifols Class B: Buy The Recovery In The U.S. Plasma Business (NASDAQ:GRFS) - Seeking Alpha

Grifols SA Share Price ADR each Representing 1 Non Voting B Share - Hargreaves Lansdown

Grifols, S.A.: Target Price Consensus and Analysts Recommendations | GRF | ES0171996087 - MarketScreener

Grifols SA: Shareholders Board Members Managers and Company Profile | ES0171996012 - MarketScreener

These European companies benefit from high health-care prices in the U.S. - MarketWatch

How International Is Your Foreign-Stock Fund? - Morningstar

GRFS or ORINY: Which Is the Better Value Stock Right Now? - Yahoo News Canada

GRF Stock Price and Chart — BME:GRF - TradingView

Top 75 Healthcare Dividend Stocks To Invest In - Insider Monkey

Finanzdaten der Grifols Sa Adr-Aktie (GRFS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie GRFS